Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Citado por Google
- Similares em SciELO
- Similares em Google
Compartilhar
Acta Medica Colombiana
versão impressa ISSN 0120-2448
Resumo
MACHADO-ALBA, Jorge Enrique et al. Lipid-lowering therapy and its effectiveness in patients from four Colombian cities. Acta Med Colomb [online]. 2016, vol.41, n.3, pp.181-186. ISSN 0120-2448.
Introduction:
The prevalence of cardiovascular disease has increased; hypercholesterolemia has been associated as a risk factor and the number of patients achieving metabolic control in some populations is unknown.
Objective:
To determine the effectiveness of lipid-lowering therapy in patients affiliated to the Colombian Health System.
Methods:
A cross-sectional study to determine the effectiveness of lipid-lowering therapy in a random sample of 211 adult patients treated with statins in four Colombian cities between 2012 and 2013. Sociodemographic, anthropometric, cardiovascular, pharmacological and paraclinical variables were obtained (total cholesterol (CT), LDL, HDL, triglycerides).
Results:
There was female predominance (56.4%), mean age 64 ± 12 years, 78.6% were treated with atorvastatin monotherapy and 19.9% with lovastatin. 43.4% of high-risk cases reached the target of C-LDL. The average initial LDL cholesterol in patients with atorvastatin was 103.7 ± 48.2 mg / dL and the final was 81.9 ± 31.2 mg / dL with an average reduction of 21.0% of the values.
This difference was statistically significant (p <0.001). Being treated in the city of Manizales (OR: 2.44; 95% CI: 1029-5789; p = 0.043) and having personal history of acute myocardial infarction (OR: 2.96; 95% CI: 1256-6980; p = 0.013) were associated with increased likelihood of controlling dyslipidemia while being treated with lovastatin (OR: 0.03; 95% CI: 0855-4614; p = 0.02) was associated with decreased likelihood of achieving control.
Discussion:
lipid-lowering therapy was performed mainly with atorvastatin followed by a low proportion of lovastatin; however patients at high cardiovascular risk treated with the latter were less likely to get metabolic control. (Acta Med Colomb 2016; 41: 181-186).
Palavras-chave : dyslipidemia; effectiveness; hydroxymethylglutaryl-CoA reductase inhibitors; treatment outcome; cardiovascular diseases; pharmacoepidemiology.